Company Revive Therapeutics Ltd Toronto S.E.

Equities

RVV

CA7615161030

Biotechnology & Medical Research

Business description: Revive Therapeutics Ltd

Sales by Activity: Revive Therapeutics Ltd

Geographical breakdown of sales: Revive Therapeutics Ltd

Managers: Revive Therapeutics Ltd

Members of the board: Revive Therapeutics Ltd

Shareholders: Revive Therapeutics Ltd

Company details: Revive Therapeutics Ltd

Bio Therapeutic Drugs

Sector

Income Statement and Estimates

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+6.67%	-11.11%

Aug. 28	Revive Therapeutics Updates on Research Study Evaluating Bucillamine for Nerve Agent Exposure	MT
Aug. 28	Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections	CI

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

Fiscal Period: June	2019	2020	2021	2022	2023

See all business segments

Fiscal Period: June	2019	2020	2021	2022	2023

See all geographic segments

Director	Title	Age	Since
Michael Frank CEO	Chief Executive Officer	-	19-12-17
Carmelo Marrelli DFI	Director of Finance/CFO	53	-

See REVIVE THERAPEUTICS LTD governance

Manager	Title	Age	Since
William Jackson BRD	Director/Board Member	-	13-12-31
Michael Frank CEO	Chief Executive Officer	-	19-12-17
Joshua Herman BRD	Director/Board Member	-	19-12-17
Christian Scovenna BRD	Director/Board Member	50	19-12-17
Andrew Lindzon BRD	Director/Board Member	63	19-12-17

Composition of the Board of Directors

Name	Equities	%	Valuation
Global X Investments Canada, Inc. 1.003 %	3,585,455	1.003 %	39 440 $
Michael Frank 0.8775 %	3,138,500	0.8775 %	34 524 $
Christian Scovenna 0.5592 %	2,000,000	0.5592 %	22 000 $
William Jackson 0.1817 %	650,000	0.1817 %	7 150 $
Joshua Herman 0.1748 %	625,334	0.1748 %	6 879 $

List of REVIVE THERAPEUTICS LTD shareholders

Revive Therapeutics Ltd.

The Canadian Venture Building 82 Richmond Street East

M5C 1P1, Toronto

+888-901-0036

http://www.revivethera.com

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
REGENERON PHARMACEUTICALS, INC.	+0.45%	-3.22%	+36.94%	+75.48%	123B
VERTEX PHARMACEUTICALS INCORPORATED	+0.84%	-0.80%	+36.73%	+151.76%	123B
ARGENX SE	-0.73%	+0.39%	+0.49%	+77.59%	32.38B
BIONTECH SE	-1.35%	+11.51%	-15.84%	-71.57%	23.6B
BEIGENE, LTD.	+6.80%	+11.93%	+0.91%	-40.01%	22.43B
GENMAB A/S	-0.15%	-3.08%	-30.21%	-35.00%	16.95B
SUMMIT THERAPEUTICS INC.	-1.18%	+89.17%	+1,292.64%	+249.23%	16.45B
WUXI APPTEC CO., LTD.	+3.35%	-2.18%	-50.27%	-72.63%	15.37B
VAXCYTE, INC.	-2.31%	+4.03%	+116.62%	+334.06%	14.05B
Average	+0.52%	+12.39%	+154.22%	+74.32%	43B
Weighted average by Cap.	+0.32%	+4.20%	+78.37%	+90.19%

See all sector performances

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

More financial data